Introduction: Atezolizumab plus bevacizumab (AB) and lenvatinib (LEN) demonstrate non-inferior survival compared with sorafenib for first-line treatment of unresectable hepatocellular carcinoma (HCC) but have not been directly compared. We retrospectively compared survival outcomes between patients treated with AB and...
K. Jobin, M. Hannouf, Mark Freeman et al.· Current Oncology· 0 citations
Predictive biomarkers for first-line treatment selection in advanced pancreatic ductal adenocarcinoma (PDAC) have been proposed, but none have been validated using data from a randomized controlled trial (RCT), which is the only design capable of unbiased assessment of differential treatment effect (DTE)....
W. Quan, D. Henault, S. M. Hasnain et al.· Cancer Research· 0 citations
CD8 T-cell populations showed the strongest methodological concordance, establishing their priority as a robust candidate biomarker for immune activation to be used in further clinical research.
C. Gaspar, Benson Z. Wu, Simone C. Stone et al.· Frontiers in Oncology· 0 citations
Better patient selection for treatment is critical to improving both cancer care and therapeutic development in oncology. The ability to predict individual patient responses to cancer treatment ahead of time would transform cancer care with substantial impact on outcomes, quality of life and cost. We generated molecula...
M. Griffiths, Jennifer J. Knox, G. O'Kane et al.· Frontiers in Artificial Inte...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.